Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Cannon

Showing results (361-370 of 706) with videos related to

Pageof 71
Sort By:
American Heart Journal|April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialStefan James, Axel Akerblom, Christopher P Cannon, et al.
American Heart Journal|July 29, 2014
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study populationMichael A Blazing, Robert P Giugliano, Christopher P Cannon, et al.
Diabetes, Obesity & Metabolism|October 25, 2017
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trialYou-Cheol Hwang, David A Morrow, Christopher P Cannon, et al.
Circulation|December 22, 2017
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Robert P Giugliano, Christopher P Cannon, Michael A Blazing, et al.
Journal of Clinical Lipidology|February 12, 2015
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trialEliot A Brinton, Uma Kher, Sukrut Shah, et al.
Clinical Cardiology|September 20, 2022
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD)Aleesha Shaik, Mikhail Kosiborod, James A de Lemos, et al.
Journal of the American Heart Association|October 17, 2022
Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMISJennifer A Rymer, Lisa A Kaltenbach, Eric D Peterson, et al.
JAMA Cardiology|October 19, 2022
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-ITSiddharth M Patel, Arman Qamar, Robert P Giugliano, et al.
Thrombosis and Haemostasis|January 17, 2003
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiologyJacqueline A Brassard, Brian R Curtis, Richard A Cooper, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2018
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 DiabetesKatherine G Garlo, William B White, George L Bakris, et al.
Pageof 71

Showing results (361-370 of 706) with videos related to

Sort By:
Pageof 71
American Heart Journal|April 1, 2009
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trialStefan James, Axel Akerblom, Christopher P Cannon, et al.
American Heart Journal|July 29, 2014
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study populationMichael A Blazing, Robert P Giugliano, Christopher P Cannon, et al.
Diabetes, Obesity & Metabolism|October 25, 2017
High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trialYou-Cheol Hwang, David A Morrow, Christopher P Cannon, et al.
Circulation|December 22, 2017
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)Robert P Giugliano, Christopher P Cannon, Michael A Blazing, et al.
Journal of Clinical Lipidology|February 12, 2015
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trialEliot A Brinton, Uma Kher, Sukrut Shah, et al.
Clinical Cardiology|September 20, 2022
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD)Aleesha Shaik, Mikhail Kosiborod, James A de Lemos, et al.
Journal of the American Heart Association|October 17, 2022
Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out-Of-Pocket Expenses? Insights From ARTEMISJennifer A Rymer, Lisa A Kaltenbach, Eric D Peterson, et al.
JAMA Cardiology|October 19, 2022
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-ITSiddharth M Patel, Arman Qamar, Robert P Giugliano, et al.
Thrombosis and Haemostasis|January 17, 2003
Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiologyJacqueline A Brassard, Brian R Curtis, Richard A Cooper, et al.
Clinical Journal of the American Society of Nephrology : CJASN|January 18, 2018
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 DiabetesKatherine G Garlo, William B White, George L Bakris, et al.
Pageof 71